Reproducibility of Multiparametric Renal Magnetic Resonance Imaging on 1.5T MRI Scanners

Launched by MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a type of imaging called multiparametric renal MRI, which helps doctors look at the kidneys in detail using a special machine called an MRI scanner. The main goal is to see how consistently this imaging technique works on 1.5 Tesla (1.5T) MRI scanners, which are commonly used. Researchers are also interested in understanding if factors like age and sex affect the results, and they will be comparing the 1.5T MRI with a stronger 3 Tesla (3T) MRI scanner for some participants.

To join this study, participants need to be healthy adults aged between 18 and 70 years, with normal blood pressure and kidney function. They should not be taking certain medications or have any ongoing serious health issues. Before any procedures, participants will need to sign a consent form to confirm they understand the study. Those who take part can expect to undergo MRI scans, which are safe and painless, and will help researchers learn more about the effectiveness of this imaging method. Additionally, the study is not yet recruiting participants, so it is still in the planning stages.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of written informed consent prior to any study specific procedures
• • Male and female subjects aged \[18-70\] years
• • Office SBP values \< 140 mmHg and DBP values ≤ 90 mmHg, under no antihypertensive therapy
• • Normal renal function defined as: estimated glomerular filtration rate \[eGFR\] ≥ 60mL/min/1.73m2 (using CKD-EPI Creatinine Equation)
• • Negative result upon urine testing for haematuria or proteinuria.
• Exclusion Criteria:
• • Previous enrollment in the present substudy
• • Contraindications to MRI including caustrophobia, pregnancy, cardiac pacemakers or other MRI-incompatible prostheses
• • Ongoing therapy (e.g. for diabetes, dyslipidemia, or any acute disease)
• • Past or current oncological pathology